Mybacs

Mybacs is a health and wellness company that manufactures and markets probiotic supplements designed to support digestive health, combining gut bacteria strains with vitamins, proteins, and minerals. The company products are formulated for daily use and travel, targeting digestive health, cardiac function, and overall wellbeing through scientifically selected probiotic strains. Mybacs emphasizes transparency in formulation, using clinically studied bacterial strains and providing detailed information about ingredient sourcing and efficacy. The company operates a direct-to-consumer business model, offering subscription-based delivery of probiotic supplements tailored to individual health needs. Founded in 2018 and headquartered in Baar, Switzerland, Mybacs has raised approximately $5.9 million in Series A funding from investors including Global Founders Capital, naturalX Health Ventures, WENVEST Capital, and Joyance Partners.